Global Health Ltd.
NSE: MEDANTAGlobal Health Ltd.: A 30-second snapshot
Global Health Ltd (MEDANTA) is a hospital network operator with a trailing PE of 64.88, a forward PE of 39.36, and 12.3% net profit margins. The stock trades at ₹1,211.9 — marginally below the 200-DMA of ₹1,215.46 and 16.76% off its 52-week high — following a Q4 FY26 quarter where net profit rose approximately 40% and revenue grew 25.3% year-on-year. Debt-to-equity stands at 25.47 with a falling debt trend, and 5-year revenue CAGR is 18.8% while 5-year earnings CAGR is -33.5%.
P/E
64.9
Forward P/E
39.4
ROE
—
Debt / Equity
25.47
Profit Margin
+12.3%
Div. Yield
+0.0%
5Y ROE > 15%
1/5
5Y FCF > 0
3/5
Quality
49/100
News
8 headlines · 7 positive · 0 negative
Global Health Q4 PAT up 39.7 pc at Rs 141.7 cr - MSN
MSN
MEDANTA: 20% revenue growth, margin gains, and rapid expansion drive strong FY 2026 performance - TradingView
TradingView
Medanta posts ₹1,195 crore in Q4 FY26, net profit soars 40% - ET HealthWorld
ET HealthWorld
Global Health Limited revenue up 25.3%, PAT 39.7% in Q4FY26 - Medical Buyer
Medical Buyer
Medanta's Financial Health Soars with 40% Profit Surge - Devdiscourse
Devdiscourse
Recent context
- ·Q4 FY26 results reported across multiple outlets on 15 May 2026 show PAT up 39.7% and revenue up 25.3% year-on-year; management cited 20% full-year revenue growth, margin expansion, and rapid bed-capacity expansion as drivers of FY26 performance.
- ·News sentiment for the most recent cycle is 7 positive, 1 neutral, 0 negative across 8 articles — all coverage concentrated on Q4 earnings, with no adverse regulatory or operational headlines in the sample.
- ·Analyst data shows 16 analysts covering the stock but consensus rating is not available in the current data pull; the forward PE of 39.36 vs trailing PE of 64.88 implies the analyst community embeds a significant earnings recovery into price targets.
Strengths
- +Q4 FY26 net profit rose approximately 40% year-on-year to ₹141.7 crore and revenue grew 25.3%, representing the most recent quarterly data point — the sharpest earnings acceleration in recent coverage.
- +5-year revenue CAGR of 18.8% demonstrates consistent top-line expansion; the gap between revenue growth and earnings growth (-33.5% over 5 years) has narrowed sharply in the most recent quarter.
- +Free cash flow was positive in 3 of available years, and debt trend is classified as falling — suggesting the capital structure is improving from its peak leverage.
- +Forward PE of 39.36 is 39% below the trailing PE of 64.88, implying consensus earnings estimates embed a material step-up in profitability relative to the trailing 12-month base.
Weaknesses
- −5-year earnings CAGR of -33.5% reflects sustained profit erosion over the measurement window; only 1 of available years recorded ROE above 15%, and ROE data is currently unavailable — returns on capital have been structurally inconsistent.
- −Debt-to-equity of 25.47 is among the highest leverage ratios seen in a listed hospital operator; this creates meaningful refinancing and interest-coverage sensitivity if operating momentum stalls.
- −Quality score of 29 ranks MEDANTA 4th of 6 peers in the sector comparison — below MAXHEALTH (54), SUNPHARMA (50), and APOLLOHOSP (42) — indicating composite fundamental quality in the lower tier of this peer set.
- −The stock has not sustained a close above the 200-DMA (₹1,215.46); 1-year price change of 3.58% materially lags peer and broader market benchmarks, and the 52-week drawdown is 16.76%.
Open questions
- ?Does the 40% quarterly PAT growth represent a durable inflection in operating leverage, or does it partly reflect a low base from elevated depreciation and interest charges in prior periods?
- ?At D/E of 25.47 with a falling debt trend, what is the absolute debt quantum relative to EBITDA, and how many years of current cash generation would be required to reach a leverage level comparable to hospital-sector peers?
- ?The 5-year earnings CAGR of -33.5% includes years of rapid capacity addition — how much of the historical earnings drag is attributable to pre-opening costs of new hospitals that are now generating revenue?
- ?MEDANTA trades at a PE of 64.88 vs MAXHEALTH at 72.52 and APOLLOHOSP at 64.64; given the quality score gap (29 vs 54), what would need to be true about margin trajectory for the valuation gap to close?
Peer comparison: Pharma
Ranks 4 of 6 on quality| Symbol | Name | P/E | ROE | Quality |
|---|---|---|---|---|
| MEDANTA | Global Health Ltd.You're viewing | 64.9 | — | 29 |
| Industry avg | across 5 peers | 47.0 | +11.8% | 37 |
| MAXHEALTH | Max Healthcare Institute Ltd. | 72.5 | — | 54 |
| SUNPHARMA | Sun Pharmaceutical Industries Ltd. | 41.3 | — | 50 |
| APOLLOHOSP | Apollo Hospitals Enterprise Ltd. | 64.6 | — | 42 |
| CIPLA | Cipla Ltd. | 29.8 | +11.7% | 24 |
| DRREDDY | Dr. Reddy's Laboratories Ltd. | 26.6 | +11.8% | 17 |
Technical state
Current price
₹1,211.90
SMA 50
₹1,093.31
SMA 200
₹1,215.46
RSI (14)
63.5 (neutral)
From 52w high
-16.8%
1Y return
+3.6%
3M return
+4.4%
50-DMA
Above
200-DMA
Below
Algorithmic support levels
Algorithmic resistance levels
Risk flags
- highDebt-to-equity of 25.47 is exceptionally elevated for a hospital operator in a non-bank sector; this leverage amplifies earnings volatility and refinancing exposure, particularly if operating cash flows moderate from the current trajectory.
- high5-year earnings CAGR of -33.5% and ROE data unavailable; only 1 of available years recorded ROE above 15%, indicating that sustained returns on capital have been absent over the measurement window despite recent quarterly improvement.
- mediumQuality score of 29 ranks MEDANTA 4th of 6 in the sector comparison; MAXHEALTH (54) and SUNPHARMA (50) score materially higher on the same composite metric, placing MEDANTA in the lower tier of peer quality.
- lowCurrent price of ₹1,211.9 is marginally below the 200-DMA (₹1,215.46); the stock has not sustained a close above this long-term moving average, with the nearest resistance identified at ₹1,244 (2.6% above current price).
Cross-section contradictions
- 5-year earnings CAGR of -33.5% and a bottom-tier quality score (4th of 6 peers) stand in contrast with Q4 FY26 PAT up 40% and revenue up 25.3%, and a forward PE of 39.36 vs trailing PE of 64.88 — the valuation gap implies the market anticipates a significant acceleration in earnings that has not yet materialized in the 5-year historical record.
For informational purposes only. Not investment advice. VivaTrades is not a SEBI-registered Investment Adviser or Research Analyst. Market data sourced from public feeds; consult a registered adviser before any investment decision.
Fundamentals & technicals: refreshed 25 Jun 2026 · refreshed daily at 01:00 IST
AI synthesis (narrative, snapshot, strengths/weaknesses, peer ranking): generated 15 May 2026 · rotates through NIFTY 500 every ~5 days